- Home
- HIO vs MREO Comparison
HIO vs MREO Comparison
Compare HIO & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIO | MREO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.0M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HIO | MREO |
|---|---|---|
| Price | $3.70 | $0.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.30 |
| AVG Volume (30 Days) | 305.3K | ★ 19.9M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $163.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.52 | $0.20 |
| 52 Week High | $4.03 | $3.84 |
Technical Indicators
Market Signals| Indicator | HIO | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 25.86 |
| Support Level | $3.68 | $0.20 |
| Resistance Level | $3.75 | $2.35 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 29.17 | 13.42 |
Price Performance
Historical ComparisonAbout HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).